Richard L. Love

TVP Management Co. LLC (TVP Management) is a venture capital subsidiary of Grayhawk Capital founded in 2006. The firm is headquartered in Phoenix, Arizona.

ImaRx Therapeutics, Inc. manufactures biopharmaceutical products. The company develops and manufactures therapies for vascular disorders associated with blood clots based on two programs, thrombolytics and sonoLysis. Its therapeutics products are approved by the US Food, Drug Administration and FDA, for the treatment of acute pulmonary embolism or blood clots in the lungs. The company was founded in 1991 and is headquartered in Los Angeles, CA

CerRx, Inc. engages in the discovery and development of anticancer drugs for cancer patients. Its products include Fenretinide and Safingol. The company was founded on December 24, 2008 and is headquartered in Lubbock, TX.

Salutaris Medical Devices, Inc. operates as a clinical-stage medical device company. It develops minimally invasive, patient-centric treatments. The firm also develops an investigational ophthalmic treatment for Wet Age-related Macular Degeneration (Wet AMD). The company was founded by Russell J. Hamilton and Laurence J. Marsteller in 2008 and is headquartered in Tucson, AZ.

Ascalon International, Inc. develops oncology drugs. The company was founded by Keith Benson on February 24, 2010 and is headquartered in Scottsdale, AZ.

Caris Molecular Profiling Institute, Inc. provides research and laboratory testing services. It offers tests to help oncologists to understand and treat cancer patients with personalized treatment plans based on the molecular characteristics of their tumors. The company offers services to the hospitals, physicians, and clinical research sponsors. Caris Molecular Profiling Institute was founded on 1996 and is headquartered in Phoenix, AZ.

SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA.

Cancer Prevention Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of therapeutic agents for the treatment and prevention of certain pre-cancerous conditions, orphan diseases and gastrointestinal conditions. The company’s pipeline consists of Gastrointestinal and Orphan. Cancer Prevention Pharmaceuticals was founded by Dr. Frank Meyskens and Gene Gerner in June 9, 2008 and is headquartered in Tucson, AZ.

Translational Accelerator LLC seeks investment opportunities in companies located in the US. The fund targets companies operating in the fields of oncology, neuroscience, developing diagnostics, medical tests or services. It provides financing for early stage capital requirements.

ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX.